Int J Food Microbiol 81(1):110
The growing interest in GLP-1 stems partly from the success of GLP-1 receptor agonist medications (such as semaglutide and liraglutide) in treating type 2 diabetes and obesity
This distinction matters enormously in the current market, where mislabeled peptides occur more frequently with high-demand compounds like retatrutide
Malaguarnera M, Gargante MP, Russo C, Antic T, Vacante M, Malaguarnera M, et al
While GIP (Glucose-Dependent Insulinotropic Peptide) is associated with fat storage, insulin secretion, and bone health
Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Top Companies AstraZeneca Novo Nordisk Eli Lilly and Company Sanofi Hypera S.A